Immunovant, Inc. (NASDAQ: IMVT) Stock Competitors & Peer Comparison
See IMVT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IMVT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IMVT | $37.04 | +3.72% | 7.6B | -13.13 | -$2.82 | N/A |
| VRTX | $547.03 | -0.16% | 138.7B | 28.75 | $19.03 | N/A |
| MRNA | $248.69 | -0.85% | 100.6B | -30.51 | -$8.15 | N/A |
| REGN | $959.41 | +4.73% | 99.2B | 21.03 | $45.63 | +0.39% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $977.58 | +0.62% | 60.8B | 35.25 | $27.73 | N/A |
| ONC | $419.98 | -0.95% | 44.9B | 73.94 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $180.70 | -6.40% | 39.1B | -20.49 | -$8.82 | N/A |
| RVMDW | $8.65 | -13.59% | 37B | -0.98 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
IMVT vs VRTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, VRTX has a market cap of 138.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while VRTX trades at $547.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas VRTX's P/E ratio is 28.75. In terms of profitability, IMVT's ROE is -0.63%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, IMVT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
IMVT vs MRNA Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MRNA has a market cap of 100.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MRNA trades at $248.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MRNA's P/E ratio is -30.51. In terms of profitability, IMVT's ROE is -0.63%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, IMVT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
IMVT vs REGN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, REGN has a market cap of 99.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while REGN trades at $959.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas REGN's P/E ratio is 21.03. In terms of profitability, IMVT's ROE is -0.63%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IMVT is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
IMVT vs VRNA Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IMVT's ROE is -0.63%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, IMVT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
IMVT vs ARGX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ARGX has a market cap of 60.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ARGX trades at $977.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ARGX's P/E ratio is 35.25. In terms of profitability, IMVT's ROE is -0.63%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, IMVT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
IMVT vs ONC Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ONC has a market cap of 44.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ONC trades at $419.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ONC's P/E ratio is 73.94. In terms of profitability, IMVT's ROE is -0.63%, compared to ONC's ROE of +0.18%. Regarding short-term risk, IMVT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
IMVT vs SGEN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IMVT's ROE is -0.63%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IMVT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
IMVT vs RVMD Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RVMD has a market cap of 39.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RVMD trades at $180.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RVMD's P/E ratio is -20.49. In terms of profitability, IMVT's ROE is -0.63%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, IMVT is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
IMVT vs RVMDW Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RVMDW has a market cap of 37B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RVMDW trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RVMDW's P/E ratio is -0.98. In terms of profitability, IMVT's ROE is -0.63%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, IMVT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
IMVT vs GMAB Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, GMAB has a market cap of 33.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while GMAB trades at $53.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas GMAB's P/E ratio is 40.60. In terms of profitability, IMVT's ROE is -0.63%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, IMVT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
IMVT vs ROIV Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ROIV has a market cap of 30.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ROIV trades at $41.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ROIV's P/E ratio is -39.81. In terms of profitability, IMVT's ROE is -0.63%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, IMVT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
IMVT vs INSM Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, INSM has a market cap of 26.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while INSM trades at $120.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas INSM's P/E ratio is -42.82. In terms of profitability, IMVT's ROE is -0.63%, compared to INSM's ROE of -0.83%. Regarding short-term risk, IMVT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
IMVT vs UTHR Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, UTHR has a market cap of 25.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while UTHR trades at $595.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas UTHR's P/E ratio is 21.30. In terms of profitability, IMVT's ROE is -0.63%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IMVT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
IMVT vs INCY Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, INCY has a market cap of 24.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while INCY trades at $122.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas INCY's P/E ratio is 16.43. In terms of profitability, IMVT's ROE is -0.63%, compared to INCY's ROE of +0.07%. Regarding short-term risk, IMVT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
IMVT vs BNTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while BNTX trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas BNTX's P/E ratio is -11.37. In terms of profitability, IMVT's ROE is -0.63%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, IMVT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
IMVT vs ALNY Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ALNY has a market cap of 21.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ALNY trades at $159.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ALNY's P/E ratio is 8.07. In terms of profitability, IMVT's ROE is -0.63%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, IMVT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
IMVT vs BGNE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IMVT's ROE is -0.63%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, IMVT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
IMVT vs DNA-WT Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IMVT's ROE is -0.63%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, IMVT is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
IMVT vs EXEL Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, EXEL has a market cap of 17.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while EXEL trades at $70.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas EXEL's P/E ratio is 20.20. In terms of profitability, IMVT's ROE is -0.63%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, IMVT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
IMVT vs NBIX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while NBIX trades at $174.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas NBIX's P/E ratio is 25.20. In terms of profitability, IMVT's ROE is -0.63%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, IMVT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
IMVT vs ASND Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ASND has a market cap of 17.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ASND trades at $259.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ASND's P/E ratio is -107.14. In terms of profitability, IMVT's ROE is -0.63%, compared to ASND's ROE of +1.90%. Regarding short-term risk, IMVT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
IMVT vs JAZZ Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while JAZZ trades at $248.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas JAZZ's P/E ratio is 9.26. In terms of profitability, IMVT's ROE is -0.63%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, IMVT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
IMVT vs BBIO Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, BBIO has a market cap of 15.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while BBIO trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas BBIO's P/E ratio is -26.16. In terms of profitability, IMVT's ROE is -0.63%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, IMVT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
IMVT vs SMMT Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, SMMT has a market cap of 13.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while SMMT trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas SMMT's P/E ratio is -14.86. In terms of profitability, IMVT's ROE is -0.63%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, IMVT is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
IMVT vs KRTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IMVT's ROE is -0.63%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IMVT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
IMVT vs HALO Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, HALO has a market cap of 11.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while HALO trades at $101.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas HALO's P/E ratio is 18.97. In terms of profitability, IMVT's ROE is -0.63%, compared to HALO's ROE of +5.44%. Regarding short-term risk, IMVT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check HALO's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
IMVT vs KYMR Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, KYMR has a market cap of 11.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while KYMR trades at $134.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas KYMR's P/E ratio is -37.25. In terms of profitability, IMVT's ROE is -0.63%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, IMVT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check KYMR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
IMVT vs TECH Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TECH's P/E ratio is 37.53. In terms of profitability, IMVT's ROE is -0.63%, compared to TECH's ROE of +0.08%. Regarding short-term risk, IMVT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
IMVT vs BMRN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while BMRN trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas BMRN's P/E ratio is 28.04. In terms of profitability, IMVT's ROE is -0.63%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, IMVT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
IMVT vs RNAM Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IMVT's ROE is -0.63%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, IMVT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check RNAM's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
IMVT vs PCVX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, PCVX has a market cap of 10.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while PCVX trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas PCVX's P/E ratio is -8.99. In terms of profitability, IMVT's ROE is -0.63%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, IMVT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
IMVT vs SYRE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, SYRE has a market cap of 10.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while SYRE trades at $106.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas SYRE's P/E ratio is -54.78. In terms of profitability, IMVT's ROE is -0.63%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, IMVT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
IMVT vs TGTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TGTX has a market cap of 10.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TGTX trades at $65.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TGTX's P/E ratio is 23.83. In terms of profitability, IMVT's ROE is -0.63%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, IMVT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check TGTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
IMVT vs MDGL Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MDGL trades at $433.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MDGL's P/E ratio is -33.83. In terms of profitability, IMVT's ROE is -0.63%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, IMVT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check MDGL's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
IMVT vs PRAX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, PRAX has a market cap of 9.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while PRAX trades at $346.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas PRAX's P/E ratio is -26.78. In terms of profitability, IMVT's ROE is -0.63%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, IMVT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check PRAX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
IMVT vs RXDX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IMVT's ROE is -0.63%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IMVT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
IMVT vs KRYS Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while KRYS trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas KRYS's P/E ratio is 38.70. In terms of profitability, IMVT's ROE is -0.63%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, IMVT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check KRYS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
IMVT vs NUVL Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas NUVL's P/E ratio is -21.79. In terms of profitability, IMVT's ROE is -0.63%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IMVT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
IMVT vs CRNX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CRNX's P/E ratio is -16.86. In terms of profitability, IMVT's ROE is -0.63%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IMVT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
IMVT vs PTGX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while PTGX trades at $134.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas PTGX's P/E ratio is 130.93. In terms of profitability, IMVT's ROE is -0.63%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, IMVT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
IMVT vs IMGN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IMVT's ROE is -0.63%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IMVT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check IMGN's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
IMVT vs APGE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas APGE's P/E ratio is -31.19. In terms of profitability, IMVT's ROE is -0.63%, compared to APGE's ROE of -0.30%. Regarding short-term risk, IMVT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
IMVT vs BPMC Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IMVT's ROE is -0.63%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, IMVT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
IMVT vs CERE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CERE's P/E ratio is -16.47. In terms of profitability, IMVT's ROE is -0.63%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IMVT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
IMVT vs CYTK Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CYTK trades at $58.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CYTK's P/E ratio is -8.11. In terms of profitability, IMVT's ROE is -0.63%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, IMVT is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check CYTK's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
IMVT vs TWST Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TWST has a market cap of 8.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TWST trades at $122.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TWST's P/E ratio is -55.22. In terms of profitability, IMVT's ROE is -0.63%, compared to TWST's ROE of -0.30%. Regarding short-term risk, IMVT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check TWST's competition here
Abivax S.A. (NASDAQ: ABVX)
IMVT vs ABVX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ABVX trades at $91.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ABVX's P/E ratio is -14.98. In terms of profitability, IMVT's ROE is -0.63%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, IMVT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
IMVT vs AXSM Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, AXSM has a market cap of 7.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while AXSM trades at $149.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas AXSM's P/E ratio is -38.97. In terms of profitability, IMVT's ROE is -0.63%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, IMVT is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check AXSM's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
IMVT vs RYTM Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RYTM trades at $112.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RYTM's P/E ratio is -36.05. In terms of profitability, IMVT's ROE is -0.63%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, IMVT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check RYTM's competition here
10x Genomics, Inc. (NASDAQ: TXG)
IMVT vs TXG Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TXG has a market cap of 7.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TXG trades at $62.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TXG's P/E ratio is -105.17. In terms of profitability, IMVT's ROE is -0.63%, compared to TXG's ROE of -0.08%. Regarding short-term risk, IMVT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check TXG's competition here
Metsera, Inc. (NASDAQ: MTSR)
IMVT vs MTSR Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IMVT's ROE is -0.63%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, IMVT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
IMVT vs IBRX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, IBRX has a market cap of 7.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while IBRX trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas IBRX's P/E ratio is -6.88. In terms of profitability, IMVT's ROE is -0.63%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, IMVT is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check IBRX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
IMVT vs ORKA Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ORKA trades at $107.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ORKA's P/E ratio is -55.24. In terms of profitability, IMVT's ROE is -0.63%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, IMVT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ORKA's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
IMVT vs ARWR Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ARWR has a market cap of 7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ARWR trades at $49.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ARWR's P/E ratio is -21.94. In terms of profitability, IMVT's ROE is -0.63%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, IMVT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ARWR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
IMVT vs CAI Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CAI trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CAI's P/E ratio is 68.64. In terms of profitability, IMVT's ROE is -0.63%, compared to CAI's ROE of +0.16%. Regarding short-term risk, IMVT is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check CAI's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
IMVT vs KOD Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, KOD has a market cap of 6.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while KOD trades at $109.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas KOD's P/E ratio is -26.22. In terms of profitability, IMVT's ROE is -0.63%, compared to KOD's ROE of -2.73%. Regarding short-term risk, IMVT is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
IMVT vs MRUS Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IMVT's ROE is -0.63%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, IMVT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
IMVT vs ACLX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IMVT's ROE is -0.63%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, IMVT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
IMVT vs RETA Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RETA's P/E ratio is -66.29. In terms of profitability, IMVT's ROE is -0.63%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IMVT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check RETA's competition here
Veradermics, Incorporated (NYSE: MANE)
IMVT vs MANE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MANE has a market cap of 6.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MANE trades at $156.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MANE's P/E ratio is -49.73. In terms of profitability, IMVT's ROE is -0.63%, compared to MANE's ROE of -0.20%. Regarding short-term risk, IMVT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check MANE's competition here
CG Oncology Inc. (NASDAQ: CGON)
IMVT vs CGON Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CGON trades at $72.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CGON's P/E ratio is -26.99. In terms of profitability, IMVT's ROE is -0.63%, compared to CGON's ROE of -0.25%. Regarding short-term risk, IMVT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CGON's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
IMVT vs LGND Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while LGND trades at $316.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas LGND's P/E ratio is 34.78. In terms of profitability, IMVT's ROE is -0.63%, compared to LGND's ROE of +0.05%. Regarding short-term risk, IMVT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check LGND's competition here
Belite Bio, Inc (NASDAQ: BLTE)
IMVT vs BLTE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while BLTE trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas BLTE's P/E ratio is -83.39. In terms of profitability, IMVT's ROE is -0.63%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, IMVT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
IMVT vs CNTA Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IMVT's ROE is -0.63%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IMVT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
IMVT vs MIRM Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MIRM trades at $94.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MIRM's P/E ratio is -6.50. In terms of profitability, IMVT's ROE is -0.63%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, IMVT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
IMVT vs TERN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TERN's P/E ratio is -51.41. In terms of profitability, IMVT's ROE is -0.63%, compared to TERN's ROE of -0.14%. Regarding short-term risk, IMVT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check TERN's competition here
Erasca, Inc. (NASDAQ: ERAS)
IMVT vs ERAS Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ERAS trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ERAS's P/E ratio is -18.06. In terms of profitability, IMVT's ROE is -0.63%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, IMVT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
IMVT vs SRRK Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while SRRK trades at $46.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas SRRK's P/E ratio is -13.51. In terms of profitability, IMVT's ROE is -0.63%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, IMVT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
IMVT vs CDTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IMVT's ROE is -0.63%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, IMVT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
IMVT vs ABCM Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IMVT's ROE is -0.63%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IMVT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
IMVT vs ISEE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IMVT's ROE is -0.63%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IMVT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
IMVT vs PTCT Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while PTCT trades at $64.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas PTCT's P/E ratio is -46.36. In terms of profitability, IMVT's ROE is -0.63%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, IMVT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
IMVT vs APLS Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas APLS's P/E ratio is 38.35. In terms of profitability, IMVT's ROE is -0.63%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IMVT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check APLS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
IMVT vs EWTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, EWTX has a market cap of 5.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while EWTX trades at $47.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas EWTX's P/E ratio is -25.71. In terms of profitability, IMVT's ROE is -0.63%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, IMVT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check EWTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
IMVT vs COGT Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while COGT trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas COGT's P/E ratio is -13.93. In terms of profitability, IMVT's ROE is -0.63%, compared to COGT's ROE of -0.71%. Regarding short-term risk, IMVT is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check COGT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
IMVT vs DNTH Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while DNTH trades at $89.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas DNTH's P/E ratio is -21.52. In terms of profitability, IMVT's ROE is -0.63%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, IMVT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
IMVT vs TVTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TVTX trades at $52.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TVTX's P/E ratio is -115.64. In terms of profitability, IMVT's ROE is -0.63%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, IMVT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check TVTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
IMVT vs ADPT Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ADPT has a market cap of 4.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ADPT trades at $29.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ADPT's P/E ratio is -73.02. In terms of profitability, IMVT's ROE is -0.63%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, IMVT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check ADPT's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
IMVT vs IONS Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, IONS has a market cap of 4.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while IONS trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas IONS's P/E ratio is -8.66. In terms of profitability, IMVT's ROE is -0.63%, compared to IONS's ROE of -1.20%. Regarding short-term risk, IMVT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check IONS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
IMVT vs DFTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while DFTX trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas DFTX's P/E ratio is N/A. In terms of profitability, IMVT's ROE is -0.63%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, IMVT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
IMVT vs FOLD Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IMVT's ROE is -0.63%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, IMVT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
IMVT vs AKRO Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IMVT's ROE is -0.63%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, IMVT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
IMVT vs ALPN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IMVT's ROE is -0.63%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IMVT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ALPN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
IMVT vs CRSP Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CRSP has a market cap of 4.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CRSP trades at $45.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CRSP's P/E ratio is -9.61. In terms of profitability, IMVT's ROE is -0.63%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, IMVT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
IMVT vs RLAY Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RLAY trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RLAY's P/E ratio is -12.56. In terms of profitability, IMVT's ROE is -0.63%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, IMVT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check RLAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
IMVT vs TNGX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TNGX trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TNGX's P/E ratio is -31.00. In terms of profitability, IMVT's ROE is -0.63%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, IMVT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
IMVT vs OPT Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas OPT's P/E ratio is -1.52. In terms of profitability, IMVT's ROE is -0.63%, compared to OPT's ROE of +1.18%. Regarding short-term risk, IMVT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
IMVT vs PRTC Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas PRTC's P/E ratio is -3.78. In terms of profitability, IMVT's ROE is -0.63%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, IMVT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check PRTC's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
IMVT vs XENE Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while XENE trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas XENE's P/E ratio is -8.96. In terms of profitability, IMVT's ROE is -0.63%, compared to XENE's ROE of -0.40%. Regarding short-term risk, IMVT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check XENE's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
IMVT vs MRTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IMVT's ROE is -0.63%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IMVT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check MRTX's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
IMVT vs AMLX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, AMLX has a market cap of 4.1B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while AMLX trades at $31.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas AMLX's P/E ratio is -21.20. In terms of profitability, IMVT's ROE is -0.63%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, IMVT is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check AMLX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
IMVT vs ABCL Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ABCL trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ABCL's P/E ratio is -22.13. In terms of profitability, IMVT's ROE is -0.63%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, IMVT is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for IMVT.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
IMVT vs CPRX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CPRX's P/E ratio is 17.49. In terms of profitability, IMVT's ROE is -0.63%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IMVT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CPRX's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
IMVT vs TARS Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, TARS has a market cap of 3.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while TARS trades at $76.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas TARS's P/E ratio is -70.42. In terms of profitability, IMVT's ROE is -0.63%, compared to TARS's ROE of -2.46%. Regarding short-term risk, IMVT is more volatile compared to TARS. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check TARS's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
IMVT vs ELVN Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while ELVN trades at $51.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas ELVN's P/E ratio is -30.65. In terms of profitability, IMVT's ROE is -0.63%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, IMVT is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
IMVT vs RYZB Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IMVT's ROE is -0.63%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IMVT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check RYZB's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
IMVT vs IOVA Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, IOVA has a market cap of 3.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while IOVA trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas IOVA's P/E ratio is -11.08. In terms of profitability, IMVT's ROE is -0.63%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, IMVT is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check IOVA's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
IMVT vs CBAY Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IMVT's ROE is -0.63%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IMVT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
IMVT vs VKTX Comparison November 2026
Immunovant, Inc. (NASDAQ: IMVT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMVT stands at 7.6B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, IMVT is priced at $37.04 on the NASDAQ, while VKTX trades at $28.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMVT currently has a P/E ratio of -13.13, whereas VKTX's P/E ratio is -5.27. In terms of profitability, IMVT's ROE is -0.63%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, IMVT is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for IMVT.Check VKTX's competition here